Investing Ideas
/
U.K. Pharmaceuticals & Biotech Undervalued based on future growth

U.K. Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

hVIVO

Market Cap: UK£56.5m

Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.

New

HVO

UK£0.083

-11.2%

-71.9%